New drug AGA2118 tested in healthy volunteers across ethnic groups
NCT ID NCT07361354
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-stage study is testing a single dose of a drug called AGA2118 in 30 healthy adults of Japanese, Chinese, and Caucasian backgrounds. Researchers want to see how the drug moves through the body and if it causes any side effects. The goal is to gather basic safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AGA2118
- What this could lead to
- If successful, this study could help determine the right dosing for future trials of AGA2118 in different ethnic groups.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. It focuses on drug levels and safety, not on treating any disease. Results may not predict effectiveness in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles EPCU
Glendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates